OVERVIEW OF ACTIVITY
Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing clinical trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists, hematologists/oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.
LEARNING OBJECTIVES
- Determine the utility of genomic assays in counseling patients with ER-positive early breast cancer about their risk of recurrence and the potential benefits of adjuvant chemotherapy.
- Counsel appropriately selected patients with breast cancer about the supportive and therapeutic role of bisphosphonates and other bone-targeted agents in disease management.
- Communicate the efficacy and safety of various chemotherapy regimens in combination with bevacizumab to patients with HER2-negative metastatic breast cancer who may be eligible for anti-angiogenic treatment.
- Evaluate the unique mechanisms of action and the emerging clinical data with novel anti-HER2 agents under investigation in breast cancer.
- Consider the efficacy and tolerability of novel agents for the later-line treatment of metastatic breast cancer.
- Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity contains both audio and print components. To receive credit, the participant should listen to the audio MP3s, read the text portion, complete the Post-test with a score of 70 percent or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/BCU211/CME. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Burstein had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Hudis — Paid Research: Merck and Company Inc, Onyx Pharmaceuticals Inc. Dr Brufsky — Consulting Agreements: Genentech BioOncology, Novartis Pharmaceuticals Corporation; Speakers Bureau: Novartis Pharmaceuticals Corporation, Sanofi. Dr Cobleigh — Advisory Committee: Eisai Inc, Genentech BioOncology, Genomic Health Inc; Paid Research: Genentech BioOncology.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, Genomic Health Inc and Sanofi.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: August 2011
Expiration date: August 2012
